CFL1 and hepatocellular carcinoma: We first examined CFL1 expression in various types of HCC cells (MHCC‐97L, MHCC‐97H, HepG2, HCC‐LM3, BEL‐7402, PLC5, and Huh7) and found the negative correlation between CFL1 expression and the half‐inhibitory concentration (IC50) of sorafenib against HCC cells (Figures S4 and S5, Supporting Information).